Table 3.

The RAS mutation status is maintained throughout disease course

Case ID#	RAS Mut.	PT	syn M[HEP] 1	syn M[HEP] 2	syn M[PUL] 1	syn M[PUL] 2	met M[HEP] 1	met M[PUL] 1	met M[PUL] 2	met M[PUL] 3
1	KRAS G12D	55.59	97.28					16.77
2	KRAS G12V	53.59	89.98		47.32	32.82
3	KRAS G12V	21.92					45.26	0 and 21.22	34
4	WT	0	0				0	0
5	KRAS G12A	24.18	9.7a		17.72	36.04
6	KRAS G12V	22.85					0	26.73
7	WT	0	0				0, 0
8	KRAS G13D	34.16	50.44		31.43			12.85
9	WT	0	0					0	0
10	WT	0					0	0
11	WT	0	0					0
12	KRAS G12A	99.74	56.72					34.15	19.63
13	KRAS G12D, G12V	19.83 (G12D)	16.44 (G12V)		5.62a and 25.72 (G12V)
14	NRAS Q61R	44.31	66.91 and 44.74		46.17

The table summarizes the RAS status and mutated allele frequency (%) throughout the disease course of 9/14 mutated CRC cases. If two metastatic lesions were resected at the same time, the RAS status is given for both

^a= sequence variant detected at below 10 % allele frequency